Last reviewed · How we verify

NCT04582123

Comparison of Cross Pin Configurations in Supracondylar Humerus Fracture Treatment: 2 Pins Versus 3 Pins

Completed NA Last updated 9 October 2020
What this trial tests

NA trial testing crossed pin configuration in Supracondylar Humerus Fracture in 45 participants. Completed in 24 January 2020.

Timeline
15 January 2015
Primary endpoint
24 January 2020
24 January 2020

Quick facts

Lead sponsorBakirkoy Dr. Sadi Konuk Research and Training Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposetreatment
Enrollment45
Start date15 January 2015
Primary completion24 January 2020
Estimated completion24 January 2020

Drugs / interventions tested

Conditions studied

Sponsor

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Who can join

Adults 1 to 12, any sex, with Supracondylar Humerus Fracture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this prospective randomized controlled trial is to evaluate and compare the outcome of the 2wire vs 3 wire crossed pin configurations in the management of supracondylar humeral fractures in children.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Interventions for treating supracondylar elbow fractures in children.
    Marson BA, Ikram A, Craxford S, Lewis SR, et al · · 2022 · cited 11× · PMID 35678077 · DOI 10.1002/14651858.cd013609.pub2

Verify or expand the search:

Other recruiting trials for Supracondylar Humerus Fracture

Currently open trials in the same condition.

Other Bakirkoy Dr. Sadi Konuk Research and Training Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04582123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing